Biotech News
Precision BioSciences Reports Third Quarter 2026 Financial Results and Provides Business Update
- PBGENE-HBV late-breaking oral presentation for ELIMINATE-B trial at AASLD's The Liver Meeting ® 2026 on November 8; data abstract scheduled for release November 5 - - Dosed first patient with PBGENE-DMD at Arkansas Children's Hospital in the Phase 1/2 FUNCTION-DMD study; initial safety data
